Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera

Trial Profile

A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ropeginterferon alfa-2b (Primary) ; Hydroxycarbamide
  • Indications Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms PROUD; PROUD-PV
  • Sponsors AOP Orphan Pharmaceuticals AG
  • Most Recent Events

    • 12 Dec 2023 Results assessing treatment response in PROUD-PV and CONTINUATION-PV trials, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 07 Dec 2023 According to AOP Orphan Pharmaceuticals GmbH media release, data from the study will Be Presented at the American Society of Hematology (ASH) 65th Annual Meeting
    • 19 Sep 2023 According to a an AOP Orphan Pharmaceuticals AG media release, data from CONTINUATION-PV and PROUD-PV presented at the Annual Meeting of the European Hematology Association and published in the journal Leukemia.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top